report-c7e1aecd1e5a6544d9d6891d3fef23c073259a73
report-c7e1aecd1e5a6544d9d6891d3fef23c073259a73
report-c7e1aecd1e5a6544d9d6891d3fef23c073259a73
HAEMATOLOGY
Test Name Result Unit Bio. Ref. Interval Method
Comment:
As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are
additionally being reported as absolute numbers of each cell in per unit volume of blood.
DHSS : Double Hydrodynamic Sequential System
HAEMATOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Comment:
Interpretation: HbA1c%
≤5.6 Normal
5.7-6.4 At Risk For Diabetes
≥6.5 Diabetes
Comments:
A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood
sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the
integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise &
recent food intake.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions,
known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.
Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified
derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.
Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean
erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test
results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.
Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the
HbA1c result does not correlate with the patient's blood glucose levels.
BIOCHEMISTRY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Lipid Profile
Cholesterol - Total 196 mg/dL Low (desirable): < 200 Enzymatic
Moderate (borderline)
200–239
High: >/= 240
Triglycerides 124 mg/dL Normal: <150, GPO, Trinder without
Borderline: 150 - 199, serum blank
High:200-499,
Very High>=500
Cholesterol - HDL 44 mg/dL Undesirable/high risk Elimination/catalase
<=40
Desirable/low risk>=60
Cholesterol - LDL 128 mg/dL Desirable: <100 Calculated
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 25 mg/dL <30 Calculated
Cholesterol : HDL Cholesterol 4.5 Ratio Desirable : 3.0-4.0 Calculated
High risk : >4
LDL : HDL Cholesterol 2.93 Ratio Desirable : 2.0-2.5 Calculated
High risk : >3.0
Non HDL Cholesterol 152 mg/dl Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220
BIOCHEMISTRY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Comment:
•Lipid profile measurements in the same patient can show physiological & analytical variations. It is recommended that 3 serial
samples 1 week apart may be tested.
•Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age and more severe
with high mortality. Dyslipidemia (abnormal lipid profile) is the major risk factor and found in almost 80% Indians.
•Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
•LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease.
•High-density lipoprotein (HDL) or “good” cholesterol can lower risk of heart disease and stroke.
•Triglyceride (TG) level also plays a major role in CVD. Indians are more prone to Atherogenic dyslipidemia, a condition
associated with high TG, low HDL-C and high LDL-C; this is associated with diabetes, metabolic syndrome and insulin resistance.
Hence high triglyceride levels also need to be treated.
•Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).
Monitoring of Non-HDLC is important in patients with high TG (e.g. diabetics, obese persons) and those already on statin
therapy.
•Lipid Association of India (LAI-2020) recommends:-
Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age (<55 yrs
in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
Fasting lipid profile is not mandatory for screening. Both fasting and non-fasting lipid profiles are equally important for
managing Indian patients.
Non-HDLC should be calculated in every subject. LAI recommends LDL-C as the primary target and Non-HDLC as the co-
primary target for initiating drug therapy.
Lifestyle modifications are of first and foremost importance for management and prevention of dyslipidemia. Among low
risk groups, treatment is started only after 3 months of lifestyle changes.
Testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered for patients in moderate risk group.
Newer treatment goals based on Risk Groups and values of LDL-C and Non-HDLC
BIOCHEMISTRY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
•As per NCEP Expert Panel (2011) guidelines, universal screening for dyslipidemia is recommended for children between 9
- 11 yrs (repeat at 17-21 yrs). Screening is not recommended before the age of 2yrs. Above the age of 2 yrs, selective screening
is done in children with family history of premature CVD or risk factors like obesity, diabetes, and hypertension.
Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report.
BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
Androstenedione*
Androstenedione Report attached.
This is an outsourced test and performed at Metropolis Lab Mumbai.
The report attached is verified by the undersigned.
BIOCHEMISTRY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Comment:
Below mentioned are the guidelines for pregnancy related reference ranges for TSH, free T3 & free T4.
Pregnancy
TSH (μIU/mL) (As per
American Thyroid FT3 (pg/mL) FT4(ng/dL)
Association)
1st trimester 0.1-2.5 2.0 - 3.8 0.7- 2.0
2nd trimester 0.2-3.0 2.0 - 3.8 0.5-1.6
3rd trimester 0.3-3.0 2.0 - 3.8 0.5-1.6
TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm
.
The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
TSH is secreted in a dual fashion: Intermittent pulses constitute 60-70% of total amount, background continuous secretion
is 30-40%.These pulses occur regularly every 1-3 hrs.
Serum TSH level changes significantly in response to even minor changes in thyroid hormones.
The determination of free T3 & free T4 has the advantage of being independent of changes in the concentrations and
binding properties of the binding proteins.
For diagnostic purposes, results should be used in conjunction with other data; e.g., symptoms, results of other thyroid
tests, clinical impressions, etc.
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
High High High Secondary Hyperthyroidism
Low High/Normal High/Normal Hyperthyroidism
Non thyroidal illness / Secondary
Low Low Low Hypothyroidism
IMMUNOLOGY
VITAMIN D (25-OH) + VITAMIN B12
Test Name Result Unit Bio. Ref. Interval Method
Vitamin D (25-OH)
Vitamin D (25-OH) 46.9 ng/ml Deficiency:< 20, CLIA
Insufficiency:20-29,
Sufficiency:30 - 100,
Toxicity possible:> 100
Comment:
Vitamin D is a fat-soluble steroid prohormone involved in the intestinal absorption of calcium and the regulation of calcium
homeostasis.
Two forms of vitamin D are biologically relevant - vitamin D3 (Cholecalciferol) and vitamin D2 (Ergocalciferol).
Both vitamins D3 and D2 can be absorbed from food but only an estimated 10-20perc. of vitamin D is supplied through
nutritional intake.
Vitamin D is converted to the active hormone 1,25-(OH)2-vitamin D (Calcitriol) through two hydroxylation reactions. The
first hydroxylation converts vitamin D into 25-OH vitamin D and occurs in the liver. The second hydroxylation converts 25-
OH vitamin D into the biologically active 1,25-(OH)2-vitamin D and occurs in the kidneys as well as in many other cells of
the body.
Most cells express the vitamin D receptor and about 3perc. of the human genome is directly or indirectly regulated by the
vitamin D endocrine system.
The major storage form of vitamin D is 25-OH vitamin D and is present in the blood at up to 1,000 fold higher
concentration compared to the active 1,25-(OH)2-vitamin D. 25-OH vitamin D has a half-life of 2-3 weeks vs. 4 hours for
1,25-(OH)2-vitamin D. Therefore, 25-OH vitamin D is the analyte of choice for determination of the vitamin D status.
Risk factors for vitamin D deficiency include low sun exposure, inadequate intake, decreased absorption, abnormal
metabolism, vitamin D resistance and and liver or kidney diseases.
Vitamin D deficiency is a cause of secondary hyperparathyroidism and diseases resulting in impaired bone metabolism (like
rickets, osteomalacia).
Recently, many chronic diseases such as cancer, high blood pressure, osteoporosis and several autoimmune diseases
have been linked to vitamin D deficiency.
The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D
IMMUNOLOGY
VITAMIN D (25-OH) + VITAMIN B12
Test Name Result Unit Bio. Ref. Interval Method
* CMIA-Chemiluminescent Microparticle Immunoassay /CLIA-Chemiluminescent immunoassay.
Vitamin B12
Vitamin B12 412.0 pg/ml 211 - 911 CLIA
Comment:
Vitamin B12 along with folate is essential for DNA synthesis and myelin formation.
Decreased levels a r e s e e n i n a n a e m i a , t e r m p r e g n a n c y , v e g e t a r i a n d i e t , i n t r i n s i c f a c t o r d e f i c i e n c y , p a r t i a l
gastrectomy/ileal damage, celiac disease, oral contraceptive use, parasitic infestation, pancreatic deficiency, treated
epilepsy, smoking, hemodialysis and advanced age.
Increased levels are seen in renal failure, hepatocelluar disorders, myeloproliferative disorders and at times with excess
supplementation of vitamins pills.
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Follicle Stimulating Hormone (FSH) 5.0 mIU/mL Follicular phase: 2.5 - CLIA
10.2,
Ovulatory phase: 3.4 -
33.4,
Luteal phase: 1.5 - 9.1,
Postmenopause: 23.0 -
116.3
Pregnancy : < 0.3
Comment:
Interpretation: FSH and LH are glycoprotein hormones which play a critical role in maintaining the normal function of the male
and female reproductive systems.FSH levels vary throughout the menstrual cycle in response to estradiol and progesterone.
Predicting ovulation
Evaluating infertility
Diagnosing pituitary disorders.
An adjunct in the evaluation of menstrual irregularities
Evaluating patients with suspected hypogonadism
Increased FSH in :
Menopause
Primary gonadal failure
Complete testicular feminization syndrome
Precocious puberty (either idiopathic or secondary to a central nervous system lesion)
Primary ovarian hypofunction in females
Primary hypogonadism in males
Gonadotrophin secreting pituitary tumours.
Drugs
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Poly cystic ovarian disease
Pituitary or hypothalamus failure
Adult Females
Follicular: 1.9-12.5,
Mid Cycle Peak: 8.7-
76.3,
Luteal Phase: 0.50-16.9,
Post Menopausal: 15.90-
54.0,
Pregnant: 0.10-1.50
Oral Contraceptives:
0.70-
5.60
Comment:
Interpretation: FSH and LH are glycoprotein hormones which play a critical role in maintaining the normal function of the male
and female reproductive systems.
Predicting ovulation
Evaluating infertility
Diagnosing pituitary disorders.
An adjunct in the evaluation of menstrual irregularities
Evaluating patients with suspected hypogonadism
Increased LH in :
Menopause
Polycystic Ovarian disease.
Endometriosis
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Primary gonadal failure
Complete testicular feminization syndrome
Precocious puberty (either idiopathic or secondary to a central nervous system lesion)
Primary ovarian hypofunction in females
Primary hypogonadism in males
Gonadotrophin secreting pituitary tumors.
Decreased LH in :
Anorexia nervosa
Ectopic steroid hormone production
GnRH Analog treatment
Drugs(Digoxin,Oral contraceptive pills ,Phenothiazines)
Advanced Prostate cancer.
Primary hypergonadism in males
Primary ovarian hyperfunction in females
In failure of pituitary or hypothalamus
PROLACTIN
Prolactin 44.35 ng/ml Nonpregnant : 2.8-29.2, CLIA
Pregnancy: 9.7 - 208.5
Postmenopausal: 1.8 -
20.3
In case of High Prolactin, repeat testing with pooled sample in fasting state is advised
Comment:
Prolactin, a polypeptide hormone secreted by the anterior pituitary, initiates and maintains lactation in postpartum period.
Clinical utility: Primarily in work-up of suspected pituitary tumor,Menstrual Irregularities,Infertility,Impotence and Galactorrhea.
Increased in: Sleep (levels rise rapidly during sleep and peak in early hours), nursing, breast stimulation, exercise,
hypoglycaemia, emotional stress, exercise, ambulation, protein ingestion, hypothyroidism, pituitary tumors (prolactinomas and
others), hypothalamic/pituitary stalk lesions,renal failure. HIV infection (21%), CHF, SLE, advanced multiple myeloma, Rathke cleft
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
cyst. Drugs intake of dopamine antagonists- phenothiazines, haloperidol , risperidone , reserpine, methyldopa , estrogens,
opiates,cimetidine.
Decreased in: Pituitary deficiency: Pituitary necrosis / infarction, Drugs: Bromocriptine, Levodopa, Pseudohypoparathyroidism
Note
* Macromolecular prolactin (macroprolactin), a complex of prolactin with IgG antibodies may lead to apparently high values in
some patients
with maintained fertility.
* PRL levels usually remain stable over time.
* Hypothalamic secretion of dopamine inhibits secretion of prolactin.
* Prolactin is secreted episodically, so multiple sampling technique i.e. pooling equal volume of sera from specimen's
drawn at 20-30 min interval is advantageous.
*In case of High Prolactin, repeat testing with pooled sample in fasting state is advised
* Please note test values may vary depending on the assay method used.
Testosterone Total
Testosterone, total 25.26 ng/dL 8.38 - 35.01 CLIA
Comment:
Stage Male Female
Tanner Stage I <7.0 - 13.06 ng/dL <7.0 - 10.06 ng/dL
Tanner Stage II <7.0 - 79.13 ng/dL <7.0 - 30.11 ng/dL
Tanner Stage III <7.0 - 499.18 ng/dL <7.0 - 30.49 ng/dL
Tanner Stage IV 79.10 - 747.17 ng/dL <7.0 - 35.19 ng/dL
Tanner Stage V 224.83 - 669.65 ng/dL 1.88 - 39.30 ng/dL
Testosterone is the major androgen in males produced by the Leydig cells of the testes.In females, it is secreted by
adrenal cortex and ovaries.
In serum, testosterone is largely bound to a specific steroid hormone-binding globulin (SHBG) (60%and to albumin (38%),
but it is the free
The total testosterone level measures both bound and free testosterone in the serum.
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Increased in: Idiopathic sexual precocity, adrenal hyperplasia (boys), adrenocortical tumors, trophoblastic disease during
pregnancy, idiopathic hirsutism, virilizing ovarian tumors, PCOD, arrhenoblastoma, virilizing luteoma, testicular feminization
(normal or moderately elevated), hyperthyroidism, Cushing’s Disease, drugs (anticonvulsants, barbiturates, estrogens, oral
contraceptives).
Decreased in: Hypogonadism (primary and secondary), orchidectomy, Klinefelter syndrome, uremia, hemodialysis, hepatic
insufficiency, ethanol, drugs (digoxin, spironolactone, acarbose), excessive exercise.
Note
Free testosterone should be measured in symptomatic patients with normal total testosterone levels.
In men, there is a diurnal variation in serum testosterone with a 20% elevation in levels in the evenings.
Physiological episodic secretion of testosterone may lead to variation in serum levels.
Time of day, age, sex, puberty, pre & post menopause have an influence on testosterone concentration.
Please note test values may very depending on the assay method used.
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Comment:
Male
Pediatric Reference Group Reference Interval ng/mL
Tanner Stage 1 4.95-144.48
Tanner Stage 2 5.02-140.06
Tanner Stage 3 2.61-75.90
Tanner Stage 4 0.43-20.14
Tanner Stage 5 1.95-21.20
Antimullerian hormone (AMH), also known as mullerian-inhibiting substance is produced by Sertoli cells of the testis in
males and by ovarian granulosa cells in females.
AMH serum concentrations are elevated in males under 2 years old and then progressively decrease until puberty, when
there is a sharp decline.
In females, serum AMH concentrations are very low at birth, peaking after puberty, decrease progressively thereafter with
age, and become undetectable at menopause. In females, AMH is considered an ovarian reserve marker. Females with
higher concentrations of AMH have a better response to ovarian stimulation and tend to produce more retrievable oocytes
than females with low or undetectable AMH. Females at risk of ovarian hyperstimulation syndrome after gonadotropin
administration can have significantly elevated AMH concentrations.
Page 17 of 24
PO No :PO1471418011-157
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
USEFUL FOR:
Decreased in:
Increased in :
Page 18 of 24
PO No :PO1471418011-157
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Comment:
Homeostatic model assessment (HOMA) is a method for assessing beta-cell function (%B)and insulin sensitivity (%S) from fasting
glucose and insulin concentrations. HOMA can be used to track changes in insulin sensitivity and beta-cell function to examine
the natural history of diabetes. Insulin sensitivity is reduced in normal subjects having first-degree relative type 2 diabetes
compared with control subjects. Changes in beta-cell sensitivity in subjects on insulin secretagogues may be useful in
determining beta-cell function over a period.
Note:
This assay cannot be used to assess beta-cell function in those taking exogenous insulin. In such patients HOMA-IR, C-
peptide Model is recommended.
The HOMA IR calculator version 2.2 accepts values only in the following validated ranges, Insulin (2.9- 57.6 mU/mL) and
Glucose (54.1-450.5 mg/dL).
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Dehydroepiandrosterone Sulphate
Dehydroepiandrostenedione sulphate 65.47 µg/dL 25.9-460.2 CLIA
(DHEA-S)
Comment:
Dehydroepiandrosterone sulfate (DHEA-S) is the most abundant adrenal androgen and also functions as a neurosteroid that is
produced by the adrenal cortex. DHEA-S is an excellent indicator of adrenal androgen production. DHEA-S exhibits only weak
androgenic activity but can be metabolized to more active androgens such as testosterone and androstenedione. Serum
concentrations decline with age and can serve as a prognostic factor in both critical illnesses and breast cancer progression.
Use:
Indicator of adrenal cortical function, differential diagnosis of virilization, and investigation of hirsutism and alopecia in women,
assessment of adrenarche and delayed puberty.
Differential diagnosis of Cushing syndrome.
Interpretation:
Increased In
Decreased In
Addison disease
Adrenal hypoplasia
Limitations
Many drugs and hormones can result in changes in DHEA-S levels.
Drugs/ hormones that can reduce DHEA-S levels include insulin, oral contraceptive drugs, corticosteroids, CNS agents that induce
hepatic enzymes (e.g., carbamazepine, clomipramine, imipramine, phenytoin), many antilipemic drugs (e.g., statins,
Page 20 of 24
PO No :PO1471418011-157
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
cholestyramine), dopaminergic drugs (e.g., levodopa/dopamine, bromocriptine), fish oil, and vitamin E.
Drugs that may increase DHEA-S levels include metformin, troglitazone, prolactin, danazol, calcium channel blockers (e.g.,
diltiazem, amlodipine), and nicotine.
Page 21 of 24
PO No :PO1471418011-157
IMMUNOLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Comment:
SHBG is a glycopotein, synthesized in the liver, binds testosterone and 5- dihydrotestosterone with high affinity, and estradiol
with a somewhat lower affinity. SHBG typically circulates at higher concentrations in women than in men, due to the higher ratio
of estrogens to androgens in women.
Uses:
Diagnosis and follow-up of women with symptoms or signs of androgen excess (e.g. PCOS and idiopathic hirsutism)
As an adjunct in monitoring sex steroid and antiandrogen therapy
As an adjunct in the diagnosis of disorders of puberty
As an adjunct in the diagnosis and follow-up of anorexia nervosa
Increased in: Hyperthyroidism, Hepatic cirrhosis, Pregnancy, Drugs: estrogens (e.g., certain oral contraceptives, phenytoin
[hepatic enzyme induction]), Use of dexamethasone in the treatment of women with hyperandrogenic hirsutism
Decreased in: Hirsutism, Acne vulgaris, Polycystic ovary syndrome, Hypothyroidism, Acromegaly, Cushing disease,
Hyperprolactinemia
Note:
SHBG can be increased with age, hyperestrogen states, marked weight loss and chronic exercise, HIV infection, and
cirrhosis.
Decreased levels may also be due to obesity and protein-losing nephropathies.
Page 22 of 24
PO No :PO1471418011-157
SEROLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
Testosterone Free
Testosterone free 1.02 pg/mL See Index EIA
Comment:
Range [pg/mL]
Age Female Male
<10 0.36 - 1.7 0.31 - 1.3
10-14 0.73 - 2.3 0.82-15.4
15-19 0.99 - 4.3 8.3 - 21.6
20-39 0.84 - 3.4 7.0 - 22.7
40-60 0.82 - 2.3 6.3 - 17.8
>60 0.66 - 2.1 2.5 - 17.8
Testosterone is the major androgen in males produced by the Leydig cells of the testes.In females, it is secreted by adrenal
cortex and ovaries. Testosterone is required for development and maintaining the male secondary sex characteristics, anabolic
growth-promoting effect and, along with FSH, maintain spermatogenesis. In men, testosterone is bound 44% to 65% to SHBG
and 33% to 50% to albumin, whereas in women testosterone is bound 66% to 78% to SHBG and 20% to 30% to albumin. The
remaining 2-3% is unbound and free.
Use: Evaluation of gonadal hormonal function.
Increased In:
Decreased In:
Page 23 of 24
PO No :PO1471418011-157
SEROLOGY
PCOS PACKAGE ADVANCED
Test Name Result Unit Bio. Ref. Interval Method
17 Alpha Hydroxy progestrone
17-Alpha Hydroxy Progesterone 0.66 ng/mL Follicular Phase - 0.3-1.0 Elisa
Luteal Phase - 0.2-2.9
After ACTH Stimulation -
<3
Pregnancy (3rd Trimester)
- 1.8-20
Comment:
Clinical Use:- The steroid 17∝-hydroxyprogesterone is produced by the adrenal cortex and gonads. 17∝-OHP has little
progestational activity, but it is of intense clinical interest because it is the immediate precursor to 11-desoxycortisol (Cpd-S).
The 21-hydroxylation of 17∝-OHP produces Cpd-S. Measurement of 17∝-OHP is a useful indirect indicator of 21-hydroxylase
activity. In congenital 21-hydroxylase deficiency, the most common variety of congenital adrenal hyperplasia (CAH), 17∝-OHP is
secreted in abundant excess. Measurement of 17∝-OHP is therefore valuable in the initial diagnosis of CAH.
Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.
Page 24 of 24
Ms. DEVIKA SUREKA D14325756 Reference: SELF VID: 240067107049192
KRISLON HOUSE, A WING ,2ND FLOOR Sample Collected At: Registered On:
SAKINAKA Kurla WEST.. Tata 1mg Technologies Private Limited
18/10/2024 06:48 PM
Tel No : +919821153820 Level Vasant Square Mall Pocket V
Sector B Vasant Kunj New Delhi-110070. Collected On:
PIN No: 400072 Processing Location:- Metropolis 18/10/2024 4:10PM
PID NO: P39024534193933 Healthcare Ltd,Unit No409-416,4th Reported On:
Age: 30 Year(s) Sex: Female Floor,Commercial Building-1,Kohinoor
Mall,Mumbai-70 18/10/2024 10:15 PM
-- End of Report --
Tests marked with NABL symbol are accredited by NABL vide Certificate no MC-2139
Page 1 of 1
Dr. ALAP CHRISTY
MBBS, MD, PGDM-HC Head -
Clinical Chemistry
Reg No.2020/12/6991
Ensuring accuracy IN every single report
Following a 3-step review process: